Impella 5.5 support in severe cardiogenic shock: outcomes from the first spanish multicentre cohort in heart transplant centres
Clicks: 1
ID: 313733
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #70 of 85 articles by views in Interdisciplinary CardioVascular and Thoracic Surgery
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
OBJECTIVES: Impella 5.5 is an established temporary mechanical circulatory support device for severe cardiogenic shock. Spain, characterised by high heart transplant activity and increasing use of controlled donation after circulatory death (DCD), provides a relevant setting to evaluate its use and outcomes. We aimed to describe clinical characteristics, trajectories, and outcomes of Impella 5.5 support in the first Spanish multicentre cohort from heart transplant centres. METHODS: Retrospective multicentre observational study including consecutive patients supported with Impella 5.5 in hospitals with active heart transplant programmes. Baseline characteristics, INTERMACS profile, additional support, complications, support duration, and in-hospital mortality were recorded. Outcomes were analysed across INTERMACS profiles. RESULTS: Ninety-three patients were included (33 INTERMACS 1, 37 INTERMACS 2, 23 INTERMACS 3). Additional support was required in 46%, mainly VA-ECLS. Device-related complications were reported as event frequencies. The predominant clinical trajectory was heart transplantation (68.8%), contrasting with international series in which long-term mechanical support and transplantation are more evenly distributed. In-hospital mortality was 43%, with a clear gradient across INTERMACS profiles 1-3 (60.6%, 37.8%, and 26.1%, respectively; p = 0.013). Mean support duration was 16 days, and more than one-third of transplants were from controlled DCD donors. CONCLUSIONS: Impella 5.5 was used as temporary mechanical circulatory support in severe cardiogenic shock and was predominantly associated with heart transplantation in a transplant-oriented healthcare system. Outcomes were closely associated with INTERMACS profile, reflecting differences in baseline severity and patient selection. Comparisons with international registries are descriptive only.
| Reference Key |
openalex_W7161037285
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | José Manuel Martínez‐Comendador, Elio Martín Gutiérrez, Daniel Ortiz Berbel, Lucía García Alcalde, Álvaro Pedraz Prieto, Christian Muñoz Guijosa, Carlos Esteban Martín López, Stefano Urso, Gregorio Rábago Juan Aracil, José J. Cuenca Castillo, Manuel Pérez-Guillén |
| Journal | Interdisciplinary CardioVascular and Thoracic Surgery |
| Year | 2026 |
| DOI |
10.1093/icvts/ivag137
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.